These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 8933041)

  • 1. Significance of the blood beryllium lymphocyte proliferation test.
    Newman LS
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):953-6. PubMed ID: 8933041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rocky Flats Beryllium Health Surveillance.
    Stange AW; Furman FJ; Hilmas DE
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):981-6. PubMed ID: 8933045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoidosis and chronic beryllium disease: similarities and differences.
    Mayer AS; Hamzeh N; Maier LA
    Semin Respir Crit Care Med; 2014 Jun; 35(3):316-29. PubMed ID: 25007084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of in vivo and in vitro measures of beryllium sensitization.
    Bobka CA; Stewart LA; Engelken GJ; Golitz LE; Newman LS
    J Occup Environ Med; 1997 Jun; 39(6):540-7. PubMed ID: 9211212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BeLPT: algorithms and implications.
    Middleton DC; Lewin MD; Kowalski PJ; Cox SS; Kleinbaum D
    Am J Ind Med; 2006 Jan; 49(1):36-44. PubMed ID: 16362939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic beryllium disease among dental technicians in Israel.
    Fireman E; Kramer MR; Priel I; Lerman Y
    Sarcoidosis Vasc Diffuse Lung Dis; 2006 Oct; 23(3):215-21. PubMed ID: 18038921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust.
    Frye BC; Quartucci C; Rakete S; Grubanovic A; Höhne K; Mangold F; Gieré R; Müller-Quernheim J; Zissel G
    Chest; 2021 Mar; 159(3):1084-1093. PubMed ID: 32926872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in identifying beryllium sensitization and disease.
    Middleton D; Kowalski P
    Int J Environ Res Public Health; 2010 Jan; 7(1):115-24. PubMed ID: 20195436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beryllium health effects in the era of the beryllium lymphocyte proliferation test.
    Maier LA
    Appl Occup Environ Hyg; 2001 May; 16(5):514-20. PubMed ID: 11370931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease.
    Maier LA; Kittle LA; Mroz MM; Newman LS
    Am J Ind Med; 2003 Jun; 43(6):592-601. PubMed ID: 12768609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT).
    Smith DE; Golden AP; Stange AW; Barker E; Mroz M; Barón AE; Ghosh D; Maier L; Cragle D; Newman LS
    Am J Ind Med; 2018 Jul; 61(7):592-604. PubMed ID: 29574954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.
    Judd NL; Griffith WC; Takaro T; Faustman EM
    Risk Anal; 2003 Dec; 23(6):1211-20. PubMed ID: 14641896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites.
    Welch L; Ringen K; Bingham E; Dement J; Takaro T; McGowan W; Chen A; Quinn P
    Am J Ind Med; 2004 Sep; 46(3):207-18. PubMed ID: 15307119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpreting borderline BeLPT results.
    Middleton DC; Mayer AS; Lewin MD; Mroz MM; Maier LA
    Am J Ind Med; 2011 Mar; 54(3):205-9. PubMed ID: 20957676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the beryllium lymphocyte proliferation test using statistical process control.
    Cher DJ; Deubner DC; Kelsh MA; Chapman PS; Ray RM
    Inhal Toxicol; 2006 Oct; 18(11):901-10. PubMed ID: 16864408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive diagnosis of chronic beryllium disease in workers exposed to hazardous dust in Israel.
    Fireman E; Mazor O; Kramer M; Priel I; Lerman Y
    Occup Environ Med; 2010 Sep; 67(9):631-5. PubMed ID: 19955573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test.
    Amicosante M; Deubner D; Saltini C
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):175-9. PubMed ID: 16315779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility.
    Schuler CR; Kent MS; Deubner DC; Berakis MT; McCawley M; Henneberger PK; Rossman MD; Kreiss K
    Am J Ind Med; 2005 Mar; 47(3):195-205. PubMed ID: 15712254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beryllium hypersensitivity and chronic beryllium lung disease.
    Santo Tomas LH
    Curr Opin Pulm Med; 2009 Mar; 15(2):165-9. PubMed ID: 19532033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of proliferation tests to evaluate the effects of complexing agents on beryllium toxicity.
    Stephan CH; Sauvé S; Fournier M; Brousseau P
    J Appl Toxicol; 2009 Jan; 29(1):27-35. PubMed ID: 18785683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.